| Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors (NCT05609331) | M.D. Anderson Cancer Center | 2022-11-17 |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax (NCT05317936) | M.D. Anderson Cancer Center | 2022-11-16 |
| Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases (NCT05195710) | M.D. Anderson Cancer Center | 2022-11-16 |
| Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling (NCT05126810) | M.D. Anderson Cancer Center | 2022-11-03 |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (NCT05092451) | M.D. Anderson Cancer Center | 2022-11-01 |
| A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer (NCT05394259) | M.D. Anderson Cancer Center | 2022-10-28 |
| A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use (NCT05589857) | M.D. Anderson Cancer Center | 2022-10-25 |
| A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. (NCT05497778) | M.D. Anderson Cancer Center | 2022-10-21 |
| Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients (NCT05511324) | M.D. Anderson Cancer Center | 2022-10-21 |
| A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) (NCT05360160) | M.D. Anderson Cancer Center | 2022-10-14 |
| A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients (NCT05053867) | M.D. Anderson Cancer Center | 2022-10-14 |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides (NCT05357794) | M.D. Anderson Cancer Center | 2022-10-13 |
| Perceptions of Hospital Care at Home for Patients With Cancer: A Qualitative Study of Cancer Providers, Patients and Caregivers. (NCT05694650) | M.D. Anderson Cancer Center | 2022-10-12 |
| First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging (NCT05335811) | M.D. Anderson Cancer Center | 2022-10-06 |
| A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma (NCT05355051) | M.D. Anderson Cancer Center | 2022-10-05 |
| Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare System (NCT07382557) | M.D. Anderson Cancer Center | 2022-09-29 |
| Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations (NCT05082025) | M.D. Anderson Cancer Center | 2022-09-27 |
| Gallium-68 PSMA-11 PET in Participants With Prostate Cancer (NCT05034562) | M.D. Anderson Cancer Center | 2022-09-26 |
| Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma (NCT05546827) | M.D. Anderson Cancer Center | 2022-09-23 |
| A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy (NCT05464719) | M.D. Anderson Cancer Center | 2022-09-23 |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma (NCT05039281) | M.D. Anderson Cancer Center | 2022-09-23 |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (NCT05365035) | M.D. Anderson Cancer Center | 2022-09-23 |
| Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla (NCT05347212) | M.D. Anderson Cancer Center | 2022-09-22 |
| A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases (NCT05048212) | M.D. Anderson Cancer Center | 2022-09-20 |
| A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma (NCT05322135) | M.D. Anderson Cancer Center | 2022-09-14 |
| Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions (NCT05327270) | M.D. Anderson Cancer Center | 2022-09-13 |
| Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma (NCT05470283) | M.D. Anderson Cancer Center | 2022-09-07 |
| A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma (NCT05273554) | M.D. Anderson Cancer Center | 2022-08-31 |
| The Effects of Spiritual Needs on Spiritual Well-Being in Patients With Brain Tumors: A Structural Equation Modeling Approach (NCT05356507) | M.D. Anderson Cancer Center | 2022-08-29 |
| Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule (NCT05003856) | M.D. Anderson Cancer Center | 2022-08-29 |
| A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care (NCT05488444) | M.D. Anderson Cancer Center | 2022-08-25 |
| Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma (NCT05535023) | M.D. Anderson Cancer Center | 2022-08-24 |
| Impact of High Dietary Fiber on Microbiome and Vaccine Responses (NCT05565586) | M.D. Anderson Cancer Center | 2022-08-23 |
| A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) (NCT05466994) | M.D. Anderson Cancer Center | 2022-08-19 |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test (NCT05243641) | M.D. Anderson Cancer Center | 2022-08-18 |
| STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis (NCT05519527) | M.D. Anderson Cancer Center | 2022-08-16 |
| Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (NCT04835597) | M.D. Anderson Cancer Center | 2022-08-15 |
| Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing (NCT05497024) | M.D. Anderson Cancer Center | 2022-08-15 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers (NCT05337735) | M.D. Anderson Cancer Center | 2022-08-05 |
| Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women (NCT05053113) | M.D. Anderson Cancer Center | 2022-07-27 |
| An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer (NCT05454488) | M.D. Anderson Cancer Center | 2022-07-25 |
| Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy (NCT05431595) | M.D. Anderson Cancer Center | 2022-07-19 |
| Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) (NCT05043012) | M.D. Anderson Cancer Center | 2022-07-18 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation (NCT04781855) | M.D. Anderson Cancer Center | 2022-07-14 |
| Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study (NCT05357469) | M.D. Anderson Cancer Center | 2022-07-14 |
| Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma (NCT05464823) | M.D. Anderson Cancer Center | 2022-07-07 |
| Use of Water Warming/Cooling Garment to Maintain a Constant Intraoperative Core Target Temperature in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Proof-of-Concept Study (NCT05474352) | M.D. Anderson Cancer Center | 2022-06-14 |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (NCT05268003) | M.D. Anderson Cancer Center | 2022-06-07 |
| A Pilot Study Assessing the Effectiveness of Use of Guided Imagery for Treatment of Pain and Symptom Management in Women With Post-mastectomy Pain Syndrome (NCT05408741) | M.D. Anderson Cancer Center | 2022-06-06 |
| TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (NCT05343013) | M.D. Anderson Cancer Center | 2022-06-06 |
| Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes (NCT03856515) | M.D. Anderson Cancer Center | 2022-06-02 |
| Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma (NCT05336383) | M.D. Anderson Cancer Center | 2022-05-31 |
| Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma (NCT05041127) | M.D. Anderson Cancer Center | 2022-05-27 |
| A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain (NCT05342454) | M.D. Anderson Cancer Center | 2022-05-23 |
| Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial (NCT05328973) | M.D. Anderson Cancer Center | 2022-05-18 |
| A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (NCT05055063) | M.D. Anderson Cancer Center | 2022-05-18 |
| Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers (NCT05205343) | M.D. Anderson Cancer Center | 2022-05-11 |
| Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (NCT05287451) | M.D. Anderson Cancer Center | 2022-05-10 |
| Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers (NCT05436327) | M.D. Anderson Cancer Center | 2022-05-06 |
| A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (NCT05285813) | M.D. Anderson Cancer Center | 2022-05-06 |
| POWER UP: Participating Online While Exercising to Recover Using Play (NCT05308407) | M.D. Anderson Cancer Center | 2022-05-04 |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer (NCT04904302) | M.D. Anderson Cancer Center | 2022-05-03 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (NCT05062317) | M.D. Anderson Cancer Center | 2022-04-26 |
| High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies (NCT05053555) | M.D. Anderson Cancer Center | 2022-04-24 |
| Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors (NCT04751396) | M.D. Anderson Cancer Center | 2022-04-20 |
| Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer (NCT04965714) | M.D. Anderson Cancer Center | 2022-04-13 |
| Single Step Lesion Annotation and Localization of Suspicious Breast Lesions (NCT05118295) | M.D. Anderson Cancer Center | 2022-04-11 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies (NCT05115630) | M.D. Anderson Cancer Center | 2022-04-08 |
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (NCT04745910) | M.D. Anderson Cancer Center | 2022-04-05 |
| A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation (NCT05118854) | M.D. Anderson Cancer Center | 2022-03-30 |
| Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome (NCT05041751) | M.D. Anderson Cancer Center | 2022-03-23 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors (NCT05010096) | M.D. Anderson Cancer Center | 2022-03-22 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer (NCT05177796) | M.D. Anderson Cancer Center | 2022-03-11 |
| Attitudes and Believes About Vaccinations in a Supportive Care Patient Population (NCT05329506) | M.D. Anderson Cancer Center | 2022-03-10 |
| Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer (NCT05144542) | M.D. Anderson Cancer Center | 2022-03-07 |
| Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (NCT05038592) | M.D. Anderson Cancer Center | 2022-03-04 |
| Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (NCT04978584) | M.D. Anderson Cancer Center | 2022-03-03 |
| Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders (NCT05293509) | M.D. Anderson Cancer Center | 2022-03-02 |
| The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms (NCT03177681) | M.D. Anderson Cancer Center | 2022-03-01 |
| Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients (NCT05290402) | M.D. Anderson Cancer Center | 2022-02-28 |
| A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (NCT05040568) | M.D. Anderson Cancer Center | 2022-02-28 |
| Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix (NCT05063916) | M.D. Anderson Cancer Center | 2022-02-28 |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer (NCT05017025) | M.D. Anderson Cancer Center | 2022-02-17 |
| Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study (NCT05169151) | M.D. Anderson Cancer Center | 2022-02-17 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT05032183) | M.D. Anderson Cancer Center | 2022-02-17 |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer (NCT05012371) | M.D. Anderson Cancer Center | 2022-02-16 |
| 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant (NCT02379377) | M.D. Anderson Cancer Center | 2022-02-15 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153) | M.D. Anderson Cancer Center | 2022-02-14 |
| Liver Cancer Prevention Randomized Control Trial (NCT05196867) | M.D. Anderson Cancer Center | 2022-02-11 |
| IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC (NCT05059470) | M.D. Anderson Cancer Center | 2022-02-11 |
| Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (NCT05038839) | M.D. Anderson Cancer Center | 2022-02-09 |
| Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study (NCT04987281) | M.D. Anderson Cancer Center | 2022-01-26 |
| A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 (NCT05055050) | M.D. Anderson Cancer Center | 2022-01-24 |
| Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases (NCT05064280) | M.D. Anderson Cancer Center | 2022-01-20 |
| Itacitinib for the Prevention of Graft Versus Host Disease (NCT04859946) | M.D. Anderson Cancer Center | 2022-01-11 |
| Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) (NCT05123807) | M.D. Anderson Cancer Center | 2022-01-07 |
| A Mobile Phone Text-based Intervention to Reduce Sedentary Behavior and Engage Communities on the Importance of Healthy Lifestyles: the TEXT2MOVE Study (NCT05217108) | M.D. Anderson Cancer Center | 2022-01-05 |
| Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy (NCT04982653) | M.D. Anderson Cancer Center | 2022-01-04 |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases (NCT05026983) | M.D. Anderson Cancer Center | 2021-12-27 |